TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: NCI Funded To Dec. 15, No Senate Figure Yet; Speedup Urged On Interferon Manufacturing, Testing October 10, 1980
